SILENCE THERAPEUTICS PLC · Data as of 2026-09-08
Q3 2026
SANRECO Phase 2 double-blind, placebo-controlled trial evaluating divesiran 6 mg (Q6W and Q12W dosing intervals) in 48 phlebotomy-dependent PV patients is ongoing with topline results on-track for the third quarter of 2026.Source filing
2027
The program is well positioned for a potential IND filing in 2027.Source filing
2027
The program is well positioned for a potential IND filing in 2027.Source filing
in 2026
Phase 1 data presentations are planned for medical and research congresses in 2026.Source filing